Navigation Links
NOSCAR announces NOTES multicenter human trials in the US
Date:7/10/2009

OAK BROOK, Ill., July 10, 2009 The Natural Orifice Surgery Consortium for Assessment and Research (NOSCAR), a joint effort of the American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), announces the first Natural Orifice Translumenal Endoscopic Surgery (NOTES) multicenter human trial in the United States. Until now, NOSCAR research efforts have focused on basic research. The next phase will involve critical human trials. Continuing research commitments from industry partners Ethicon Endo-Surgery, Olympus America Inc. and Stryker Medical will provide funds to support the study in this emerging transdisciplinary therapy. The landmark study was announced at the 4th International Conference on NOTES in Boston where nearly 300 physicians and industry representatives gathered to learn the latest information about the science and technology of the medical platform.

"NOSCAR is taking a big step forward later this year with the commencement of the first NOTES multicenter human trial in the U.S. We are grateful to our partners at Ethicon Endo-Surgery, Olympus America Inc. and Stryker Medical for helping make the study possible," said Michael L. Kochman, MD, NOSCAR Research Subcommittee co-chair.

The human studies are expected to begin later this year. NOSCAR leadership is currently finalizing the design for a prospective multicenter trial of NOTES cholecystectomy (gallbladder removal) versus conventional laparoscopic cholecystectomy. NOSCAR will be granting funds to selected institutions to conduct these trials. Institutions participating in the trial have demonstrated a strong commitment to developing the basic science that forms the foundation of NOTES and have already performed human NOTES cases under an Institutional Review Board protocol; approximately 200 patients will be enrolled in the clinical trial.

NOSCAR will make additional announcements regarding the participating institutions, study protocols and when studies will commence. ACI, a Clinical Research Organization based in Pennsylvania, has been retained to provide data collection and report preparation services for the study.

"We are delighted that the research and science to date has led us to the point where we can begin conducting human trials. The careful, responsible introduction of NOTES is our utmost concern; this study will provide the basis for such an introduction," said Steven D. Schwaitzberg, MD, NOSCAR Research Subcommittee co-chair.


'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Related medicine news :

1. NOSCAR announces 2008 NOTES Research Award winners
2. NOSCAR(R) Announces NOTES(R) Multicenter Human Trials in the U.S.
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: